Protara Therapeutics, Inc. (TARA) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−3.1x

Market Cap

$232.84M

MomentumView details →

1D Return

−0.76%

YTD Return

−26.17%

RSI (14)

48.5

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−3.1x

Market Cap

$232.84M

RSI (14)

48.5

MomentumView details →

1D Return

−0.76%

YTD Return

−26.17%

SummaryUpdated Jun 1, 2026

Protara Therapeutics, Inc. (NASDAQ:TARA) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in New York, New York. Originally incorporated as ArTara Therapeutics, Inc., the company changed its name to Protara Therapeutics in May 2020. The company focuses on identifying and advancing transformative therapies for the treatment of cancer and rare diseases, with a particular emphasis on developing innovative cell therapies and substrate replacement treatments for underserved patient populations.

Ask drillr about Protara Therapeutics, Inc. →

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−43.40%

ROA (TTM)

−39.76%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+16.05%

FCF YoY

−45.52%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+38.25%

EBITDA YoY

−31.04%

EarningsView details →

EPS (Actual)

−$0.36

EPS Surprise

−10.53%

Beats (12Q)

8/12

Next Q EPS Est

−$0.37

Avg Surprise (4Q)

5.24%

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.02x

Current Ratio

10.97x

Quick Ratio

10.97x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−70.02M

Op. CF (TTM)

−64.80M

Next earningsNov 9, 2026 →

Latest newsMore news →

Protara Therapeutics reported a net loss of $21.7 million for Q2 2026, with research and development expenses of $17.0 million and general and administrative expenses of $6.4 million.25d ago

Leonardo Viana Nicacio, M.D. resigned as Chief Medical Officer of Protara Therapeutics, Inc., effective June 26, 2026.68d ago

Similar companies

Innate Pharma S.A.IPHA Greenwich LifeSciences, Inc.GLSI I-MabIMAB Acumen Pharmaceuticals, Inc.ABOS Sol-Gel Technologies Ltd.SLGL Tonix Pharmaceuticals Holding Corp.TNXP Find similar companies →

Latest newsMore news →

Protara Therapeutics reported a net loss of $21.7 million for Q2 2026, with research and development expenses of $17.0 million and general and administrative expenses of $6.4 million.25d ago Leonardo Viana Nicacio, M.D. resigned as Chief Medical Officer of Protara Therapeutics, Inc., effective June 26, 2026.68d ago